Loading patent…
AssigneeUniversity of Washington
InventorsDavid M. Koelle, Lawrence Corey
Estimating the term…
The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
A pharmaceutical composition comprising an isolated herpes simplex virus (HSV) polypeptide, wherein the polypeptide comprises a UL19, UL21, UL49 or UL50 protein or a fragment thereof, and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising an isolated HSV polypeptide and a pharmaceutically acceptable carrier, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of:
A polynucleotide that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of:
A pharmaceutical composition comprising a polynucleotide that encodes an HSV polypeptide, wherein the polypeptide comprises a UL19, UL21, UL49 or UL50 protein or a fragment thereof, and a pharmaceutically acceptable carrier.
A recombinant virus genetically modified to express a UL19, UL21, UL49 or UL50 protein or a fragment thereof.
A method of producing immune cells directed against HSV comprising contacting an immune cell with an antigen-presenting cell, wherein the antigen-presenting cell is modified to present an epitope included in a UL19, UL21, UL49 or UL50 protein or in a polypeptide selected from the group consisting of:
A method of treating or preventing an HSV infection in a subject comprising administering an antigen-presenting cell modified to present an epitope included in a UL19, UL21, UL49 or UL50 protein or in a polypeptide selected from the group consisting of:
Dependencies are inferred from the claim text.